Utilization of Rad51C promoter for transcriptional targeting of cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• Targeting cancer cells specifically while sparing normal tissue is a key goal in cancer research.
• Rad51 promoter has been explored for tumor-specific gene targeting, but its large size poses limitations for gene therapy.
• Rad51 paralogs (Rad51B, Rad51C, Rad51D) and Rad52 are investigated as potential alternative tumor-specific promoters.

Purpose of the Study:

• To identify novel tumor-specific promoters for cancer gene therapy.
• To evaluate the potential of Rad51 paralogs and Rad52 as cancer-targeting elements.
• To assess the efficacy of a Rad51C promoter-driven therapeutic strategy.

Main Methods:

• Expression analysis of Rad51 paralogs (Rad51B, Rad51C, Rad51D) and Rad52 in normal and tumor cell lines.
• Characterization of the Rad51C promoter activity in cancer versus normal cells.
• Construction and testing of a gene therapy vector utilizing the Rad51C promoter to drive diphtheria toxin A expression.

Main Results:

• Rad51C showed significant overexpression in cancer cells (6-fold mRNA, 9-fold protein).
• The Rad51C promoter fragment demonstrated a 300-fold higher activity in cancer cells compared to normal cells.
• A Rad51C promoter-driven diphtheria toxin A construct effectively killed cancer cells with minimal toxicity to normal cells.

Conclusions:

• Rad51C is a promising tumor-specific promoter for cancer gene therapy.
• The Rad51C promoter fragment offers a viable tool for transcriptional targeting of cancer cells.
• Targeting the homologous recombination pathway via Rad51C presents a potential therapeutic strategy.